DAR No 8. Saxagliptin (Onglyza®) in type 2 diabetes

Content tools

Share it

The third DPP-4 inhibitor... and the last one in line

Saxagliptin is a hypoglycaemic agent indicated as combined therapy with metformin, sulphonylureas or thiazolidinediones.
It is not authorized as monotherapy, or in triple therapy, or as combined therapy at the onset of diabetes treatment, or in combination with insulin.
Its effect on mortality and morbidity has not been evaluated.
Its safety profile has not been sufficiently established.
Monitoring of possible skin disorders is recommended.
It does not present any advantage over other gliptins.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *